More importantly, the use of a newly generated recombinant protein based on the TMEM219 extracellular domain (ecto-TMEM219), which inhibits the IGFBP3/TMEM219 pathway, protected beta cells in vitro and prevented the onset of hyperglycemia in murine models of diabetes in vivo. Here, TMEM219 is linked to diabetes mellitus.